Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.